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Abstract
Women with early-stage breast cancer have reduced peak exercise oxygen
uptake (peak VO2). The purpose of this study was to evaluate peak VO2 and
right (RV) and left (LV) ventricular function prior to adjuvant chemotherapy.
Twenty-nine early-stage breast cancer patients (mean age: 48 years) and 10
age-matched healthy women were studied. Participants performed an upright
cycle exercise test with expired gas analysis to measure peak VO2. RV and LV
volumes and function were measured at rest, submaximal and peak supine
cycle exercise using cardiac magnetic resonance imaging. Peak VO2 was signif-
icantly lower in breast cancer patients versus controls (1.7  0.4 vs.
2.3  0.5 L/min, P = 0.0013; 25  6 vs. 35  6 mL/kg/min, P = 0.00009).
No significant difference was found between groups for peak upright exercise
heart rate (174  13 vs. 169  16 bpm, P = 0.39). Rest, submaximal and
peak exercise RV and LV end-diastolic and end-systolic volume index, stroke
index, and cardiac index were significantly lower in breast cancer patients ver-
sus controls (P < 0.05 for all). No significant difference was found between
groups for rest and exercise RV and LV ejection fraction. Despite preserved
RV and LV ejection fraction, the decreased peak VO2 in early-stage breast
cancer patients prior to adjuvant chemotherapy is due in part to decreased
peak cardiac index secondary to reductions in RV and LV end-diastolic
volumes.
Introduction
Breast cancer is the most frequently diagnosed malignancy
among women and the second leading cause of cancer
mortality in the United States (Siegel et al. 2017). During
the past three decades, the breast cancer mortality rate
has decreased by nearly 40% as a result of advances in
prevention, early detection, and treatment (American
Cancer Society, 2017). Despite improved survival, breast
cancer survivors are at increased at risk of developing car-
diovascular disease that is due, in part, to an unhealthy
lifestyle associated with sedentary deconditioning
(Armenian et al. 2016; Park et al. 2017; Chapman et al.
2008; Patnaik et al. 2011; Bradshaw et al. 2016).
Breast cancer patients have severely reduced exercise
tolerance, measured objectively as decreased peak oxygen
uptake (peak VO2), that is associated with decreased qual-
ity of life and survival (McNeely et al. 2006; Jones et al.
2007a,2011,2012. Jones et al. (2012) reported that peak
VO2 was 27% lower in breast cancer survivors compared
to age- and sex-matched sedentary predicted values.
Moreover, nearly one-third of survivors had a peak VO2
below the threshold of independent living (Jones et al.
2012). The marked exercise intolerance has been linked to
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a reduced peak exercise cardiac output secondary to a
reduced stroke volume, as peak heart rate (HR) was not
different between breast cancer survivors and controls
(Jones et al. 2007a).
It is currently not known whether women with reduced
exercise capacity are predisposed to breast cancer or
whether exercise intolerance is acquired as a result of can-
cer therapy. There is a paucity of studies that have mea-
sured peak VO2 in breast cancer patients prior to
undergoing adjuvant chemotherapy. A systematic review
by Peel et al. (2014) reported that peak VO2 was 17%
lower in breast cancer patients prior to adjuvant therapy
compared to age-matched healthy sedentary predicted val-
ues. To date, no study has measured exercise cardiac
function in breast cancer patients prior to undergoing
chemotherapy. Furthermore, all prior studies have
focused primarily on left ventricular (LV) function, there-
fore uncertainty remains regarding right ventricular (RV)
performance during exercise. Given this uncertainty, the
aim of this study was to test the hypothesis that the
impaired peak VO2 in breast cancer patients prior to
adjuvant chemotherapy is attributable to decreased exer-




Women aged 18–70 years with newly diagnosed, histolog-
ically confirmed early-stage breast cancer scheduled for
anthracycline-based chemotherapy were recruited via col-
laborating breast surgeons and oncologists from local hos-
pitals in the Melbourne metropolitan area. Patients with
structural heart disease, sustained cardiac arrhythmias, or
a contraindication to cardiac magnetic resonance imaging
were excluded. Age- and sex-matched control subjects
were recruited from an advertisement to staff of the Baker
Heart and Diabetes Institute and the wider community.
Volunteers involved in competitive sport or enrolled in a
structured exercise training program were excluded.
Protocol overview
The study protocol was approved by the Alfred Health
Institutional Review Board and written informed consent
was obtained from all subjects. Breast cancer patients per-
formed all tests prior to anthracycline treatment.
Cardiopulmonary exercise testing
Incremental exercise testing was performed on an elec-
tronically braked upright cycle ergometer (Lode,
Gronigen, Netherlands) with an initial power output of
10-25 W and was progressed by 10–30 W per minute
until volitional exhaustion. Expired gas analysis was per-
formed using a commercially available metabolic mea-
surement system (True One 2400, Parvomedics, UT),
with the highest value obtained over 30 sec used as the
peak VO2 value. HR was continuously measured (1200W
RF Wireless System, Norav, FL), whereas blood pressure
(Suntech, Tango, NC) was measured every 2 min during
exercise.
Biochemistry
Peripheral venous blood samples were taken 10 min after
completion of exercise cardiac magnetic resonance
(cMRI) testing to measure B-type natriuretic peptide
(BNP) and troponin I. Hemoglobin values were obtained
from patient medical records.
Rest and exercise cardiac magnetic
resonance imaging cMRI
Cardiac images were acquired with a Siemens MAGNE-
TOM Prisma 3T scanner with a 5-element phased-array
coil (Siemens, MAGNETOM Prisma). Ungated, real-time,
steady-state free-precession cine imaging was performed
without cardiac/respiratory gating. Forty to 75 consecu-
tive frames were acquired every 36–38 msec at each of
13–18 contiguous 8-mm slices in the short-axis (SAX)
plane, and 50 consecutive frames were acquired at
approximately the same temporal resolution for 11–15
contiguous 8-mm slices in the horizontal long axis (HLA)
plane. Scan duration was approximated to include one
full respiratory cycle per slice (~120 and ~90 sec at rest
for SAX and HLA planes, respectively, ~4–7 heart beats/
slice) for gating of cardiac translation (La Gerche et al.
2013).
RV and LV volumes were generated by manually trac-
ing the endocardium in the SAX plane and using the disk
summation method (La Gerche et al. 2013). To minimize
cardiac translation error, contours were traced in end
diastole and end systole for each slice manually gated to
respiration. SAX contour transection points with the HLA
plane were displayed for referencing of the atrioventricu-
lar valve plane. Trabeculations and papillary muscles were
considered part of the ventricular blood pools. HR was
determined by generating an anatomical M-mode image
from the SAX plane stack. Cardiac index was calculated
as the average of RV and LV stroke volume (indexed to
body surface area) multiplied by HR. Physiologic data
was synchronized with images for offline data analysis.
Images were analyzed with RightVol (Right Volume Leu-
ven, Leuven, Belgium), a MatLab software adjunct.
2019 | Vol. 7 | Iss. 1 | e13971
Page 2
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Exercise Intolerance Prior to Chemotherapy R. I. Beaudry et al.
After resting images were obtained, subjects cycled on a
MRI compatible ergometer (MR Ergometer Pedal, Lode,
Groningen, Netherlands) at an intensity equal to 20, 40
and 60% of peak power output obtained during the
upright incremental cycle exercise test. These workloads
will subsequently be referred to as rest and low, moderate,
and peak intensity. Each stage of exercise was maintained
for 1–3 min; 30 sec to 1 min to achieve a physiological
steady-state and 1–2 min for image acquisition. We previ-
ously determined that 66% of the peak power during
upright cycling corresponded to peak exercise in a supine
position (Roest et al. 2001).
Statistical analysis
Comparison between groups for continuous variables was
assessed using student t tests. Pearson correlation was
used to determine linear correlations between variables.
Two-Way ANOVA with post hoc Bonferroni testing was
used to compare cardiac volumes and ejection fraction at
different exercise intensities. Unless otherwise stated, data
are presented as mean (standard deviation). A two-sided
P < 0.05 was determined as significant. All statistical anal-
yses were performed with SPSS (version 24 IMB SPSS
Statistics, Armonk, NY) statistics software.
Results
Participant characteristics
Twenty-nine women with early breast cancer and 10 age-
and sex-matched healthy controls agreed to participate in
this study. No significant difference was found between
breast cancer patients and healthy controls for age, height,
weight, body mass index, body surface area, hemoglobin,
brain natriuretic peptide, or troponin I. However, body
mass index tended to be higher in the breast cancer
group, as fewer healthy control subjects were overweight,
and none were obese (Table 1). Fourteen and fifteen
breast cancer patients were scheduled to receive anthracy-
clines in a neoadjuvant and adjuvant setting, respectively.
Cardiopulmonary exercise performance
during upright cycle exercise
Peak exercise power output and VO2 were significantly
lower in breast cancer patients compared to healthy con-
trols (38  21% and 29  17% lower, respectively,
Table 2). Peak exercise systolic and diastolic blood pres-
sure and HR were not significantly different between
groups. A sensitivity analysis was conducted to address
the potential confounder of surgery prior peak VO2 test-
ing. Fifteen breast cancer patients who had undergone
breast surgery (local resection or mastectomy, scheduled
for adjuvant chemotherapy) were compared with the 14
patients planned for surgery after chemotherapy (neoad-
juvant treatment strategy). No significant difference was
found between these groups for age, BMI, BSA, peak
power output, VO2 (L/min or mL/kg/min) or cardiac
output (Data supplement).
Cardiac volumes and index at rest,
submaximal, and peak supine cycle exercise
Complete cMRI data were obtained in 26 of 29 breast
cancer patients (one subject withdrew from the study
prior to cMRI testing, HR could not be measured accu-
rately during peak exercise in one subject – volumes, but
not peak cardiac output, are included – one image set
was excluded due to artifact) and 10 healthy controls.
No significant difference was found between groups for
rest, submaximal and maximal RV and LV ejection frac-
tion. A significant main group effect was found for RV
and LV end-diastolic volume index, end-systolic volume
Table 1. Participant characteristics.
Parameter BC (n = 29) HC (n = 10) P value
Age (years) median [range] 48 (12) 51 [19–68] 48 (12) 52 [30-66] 0.98
Height (cm) 165 (9) 166 (7) 0.67
Weight (Kg) 72 (19) 66 (9) 0.31
Body mass index (kg/m2) 26.7 (6.9) 23.8 (2.1) 0.21
Normal, n (%) 16 (55) 8 (80) -
Overweight, n (%) 9 (31) 2 (20) -
Obese, n (%) 4 (14) - -
Body surface area (m2) 1.77 (0.22) 1.73 (0.15) 0.49
Hemoglobin (g/dL) 13.0 (1.4) (n = 26) 13.2 (0.5) 0.68
BNP 36.9 (33.6) (n = 26) 26.9 (16.5) (n = 9) 0.38
Troponin I 2.9 (1.3) (n = 26) 3.3 (2.9) 0.58
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index, stroke index, and cardiac index with values being
lower in breast cancer patients compared to controls
(Figs. 1–3). A significant main (exercise) intensity effect
was found for RV and LV stroke index and ejection frac-
tion being higher while RV and LV end-systolic volume
index were lower during exercise compared to rest in
both breast cancer and controls (Figs. 1–3). A significant
group by intensity interaction was found for cardiac index
with breast cancer patients having lower values during
submaximal and peak exercise compared to controls.
Finally, a significant positive relationship was found
between peak VO2 and cardiac output (Fig. 4).
Discussion
Consistent with limited prior data, we confirmed that,
relative to healthy age-matched controls, women with
breast cancer had reduced exercise capacity prior to can-
cer therapy. We extend prior research by examining the
cardiac mechanisms underpinning this exercise impair-
ment by comparing changes in RV and LV volumes mea-
sured during peak supine cycle exercise. The principal
new finding was that the reduced peak VO2 in breast can-
cer patients versus healthy controls was due, in part, to a
reduced maximal cardiac index. In turn, the reduced peak
Table 2. Cardiopulmonary exercise performance during peak upright cycle exercise.
Parameter Breast cancer (n = 29) Healthy control (n = 10) P Value
Power output (W) 142 (47) 228 (51) 0.00003
VO2 (L/min) 1.7 (0.4) 2.3 (0.5) 0.0013
VO2 (mL/kg/min) 25 (6) 35 (6) 0.00009
HR (bpm) 174 (13) 169 (16) 0.39
Systolic blood pressure (mmHg) 185 (27) 180 (28) 0.83
Diastolic blood pressure (mmHg) 93 (16) 84 (19) 0.18
Figure 1. Left ventricular end-diastolic volume index (A), end-systolic volume index (B), stroke volume index (C), and ejection fraction (D) at
rest, submaximal and peak supine cycle exercise. *Significant main group (breast cancer vs. control) effect; †Significant main intensity (low,
moderate, and peak exercise vs. rest).
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exercise cardiac index was due to a reduced RV and LV
stroke index and end-diastolic volume index as no signifi-
cant difference was found between groups for RV and LV
ejection fraction.
The mechanisms responsible for reduced biventricular
end-diastolic volumes prior to adjuvant chemotherapy
were not studied, however, sedentary aging may play a
role. Bhella et al. (2014) have shown that lifelong seden-
tary (exercise <2 times per week) and casual exercisers
Figure 2. Right ventricular end-diastolic volume index (A), end-systolic volume index (B), stroke volume index (C), and ejection fraction (D) at
rest, submaximal and peak supine cycle exercise. *Significant main group (breast cancer vs. control) effect; †Significant main intensity (low,
moderate, and peak exercise vs. rest).
Figure 3. Heart rate and cardiac index at rest, submaximal, and
peak supine cycle exercise. *Significant main group (breast cancer
vs. control) effect; †Significant main intensity (low, moderate, and
peak exercise vs. rest); ‡Significant group by intensity interaction.
Figure 4. Relationship between peak VO2 (upright cycle exercise)
and peak cardiac output (supine cycle exercise).
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(exercise 2–3 times per week) have lower peak oxygen
uptake, LV mass and LV distensibility than those who
exercise >3 times per week. Despite increased LV stiffness,
less active individuals did not have impaired systolic
impairment or abnormalities, closely mirrored by our
findings (Bhella et al. 2014). One plausible explanation
for our finding of lower functional capacity in breast can-
cer patients is sedentary deconditioning due to reduced
mobility and physical activity following surgery. However,
when we compared patients who had undergone surgery
versus those who had not received any treatment (sur-
gery, chemotherapy, or radiation), no difference in peak
VO2 was observed. This null finding is not inconsistent
with patient surveys; patients were referred to the study
after surgical recovery and had returned to baseline based
on subjective self-report of symptoms. Accordingly, such
a substantial decrement in peak VO2 and ventricular end-
diastolic volumes are better explained by longer term
reductions in physical activity volume and intensity
(Bhella et al. 2014).
Given that the breast cancer patients’ in our study had
peak VO2 values that were approximately 30% lower than
controls, it is plausible that the reduced biventricular
end-diastolic volume may be due to increased LV stiff-
ness. Furthermore, a cluster of comorbidities associated
with a sedentary lifestyle are also linked with increased
breast cancer incidence and mortality, it is perhaps rea-
sonable to hypothesize that a lower peak VO2 may be an
additional clinical breast cancer risk factor and be associ-
ated with reduced survival after diagnosis (Jones et al.
2012). Moreover, obesity, metabolic syndrome, and mus-
cle atrophy have been associated with increased breast
cancer incidence (Bellocco et al. 2016; Caan et al. 2018;
Gathirua-Mwangi et al. 2018; Guo et al. 2018) and it has
been hypothesized that this may be due to a mild proin-
flammatory state and attenuated immune response (Khan
et al. 2013; Gathirua-Mwangi et al. 2018). On the other
hand, exercise inhibits inflammation in adipose tissue and
creates unfavorable conditions for cancer, (Dieli-Conwright
et al. 2018) a reduction in breast cancer incidence and
improved survival (McTiernan et al. 2003; Moore et al.
2016). Thus, it is perhaps not entirely unexpected that
patients diagnosed with breast cancer may have, on average,
performed less exercise thereby resulting in reduced cardiac
size and lower exercise capacity, as observed in our current
study.
In accordance with the “multiple hit” hypothesis, the
reduced peak VO2 in breast cancer survivors is attributed,
in part, to the adverse cardiac effects of chemotherapy
(Jones et al. 2007a,b; Haykowsky et al. 2016). To date,
only one study has measured VO2 and its determinants
during peak exercise in breast cancer survivors (n = 47,
mean age: 59 years, mean time postchemotherapy:
38 months) and age-matched healthy controls (n = 11).
The main finding was that the decreased peak VO2 (20%)
in breast cancer survivors versus controls was due to a
significantly lower peak exercise cardiac output and stroke
volume, as HR and calculated arterial-venous oxygen dif-
ference were not significantly different between groups
(Jones et al. 2007a). We extend these findings and show
reduced maximal exercise cardiac output and peak VO2
prior to undergoing chemotherapy. Importantly, our find-
ing that 45% of the variance in peak VO2 was explained
by cardiac output (Fig. 4) suggests that non-cardiac,
peripheral factors (e.g., muscle blood flow and/or O2
extraction) also play an important role in limiting peak
VO2 prior to adjuvant chemotherapy.
Clinical implications
Given that peak VO2 declines by 10% after 12 weeks of
chemotherapy (equal to what is observed after a decade
of sedentary aging), (Hornsby et al. 2014) our finding
that breast cancer patients have marked exercise intoler-
ance and impaired exercise cardiac output (and likely
impaired peripheral determinants) reserve prior to adju-
vant chemotherapy, suggests that interventions that atten-
uate the decline in peak VO2 may be an important target
of therapy. Indeed, exercise training is an effective therapy
to improve peak VO2 during adjuvant chemotherapy;
(Jones et al. 2011) however, the optimal exercise training
program and mechanisms responsible for this favorable
adaptation remain uncertain (Scott et al. 2018).
Limitations
A limitation of this study was that peak VO2 testing was
performed during upright exercise while cardiac volumes
were measured in the supine position, therefore the
mechanisms underpinning the reduced maximal cardiac
output may differ between groups in the upright position.
However, this is unlikely as peak HR was not different
between groups during peak upright exercise. Also, breast
cancer patients and healthy controls relied on a decrease
in RV and LV end-systolic volume to increase stroke
index and ejection fraction from rest to peak exercise.
Given that breast cancer patients displayed evidence of
sedentary aging, we contend that biventricular end-diasto-
lic volume would remain lower during upright exercise
given this remodeling pattern is associated with decreased
cardiac distensibility.
Conclusion
Despite preserved rest, submaximal and peak exercise RV
and LV ejection fraction, breast cancer patients prior to
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adjuvant chemotherapy have marked exercise intolerance,
related to decreased maximal cardiac index, secondary to
reduced RV and LV end-diastolic volume. Peripheral,
noncardiac factors may also play a prominent role in lim-
iting exercise tolerance prior to adjuvant chemotherapy.
Accordingly, interventions that improve cardiovascular
and skeletal muscle function, such as exercise training,
initiated at the time of diagnosis may attenuate the
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